Journal article
bioRxiv, 2021
APA
Click to copy
Antiochos, B., Fenaroli, P., Rosenberg, A., Baer, A., Sohn, J., Li, J., … Rosen, A. (2021). The DNA sensors AIM2 and IFI16 are NET-binding SLE autoantigens. BioRxiv.
Chicago/Turabian
Click to copy
Antiochos, B., P. Fenaroli, A. Rosenberg, A. Baer, J. Sohn, Jessica Li, M. Petri, et al. “The DNA Sensors AIM2 and IFI16 Are NET-Binding SLE Autoantigens.” bioRxiv (2021).
MLA
Click to copy
Antiochos, B., et al. “The DNA Sensors AIM2 and IFI16 Are NET-Binding SLE Autoantigens.” BioRxiv, 2021.
BibTeX Click to copy
@article{b2021a,
title = {The DNA sensors AIM2 and IFI16 are NET-binding SLE autoantigens},
year = {2021},
journal = {bioRxiv},
author = {Antiochos, B. and Fenaroli, P. and Rosenberg, A. and Baer, A. and Sohn, J. and Li, Jessica and Petri, M. and Goldman, D. and Mecoli, C. and Casciola‐Rosen, L. and Rosen, A.}
}
Nucleic acid binding proteins are frequently targeted as autoantigens in systemic lupus erythematosus (SLE) and other interferon (IFN)-linked rheumatic diseases. The AIM-like receptors (ALRs) are IFN-inducible innate sensors that form supramolecular assemblies along double-stranded DNA of various origins. Here, we identify the ALR Absent in melanoma 2 (AIM2) as a novel autoantigen in SLE, with similar properties to the established ALR autoantigen interferon-inducible protein 16 (IFI16). Our SLE cohort revealed a frequent co-occurrence of anti-AIM2, anti-IFI16 and anti-DNA antibodies, and higher clinical measures of disease activity in patients positive for antibodies against these ALRs. We examined neutrophil extracellular traps (NETs) as DNA scaffolds on which these antigens might interact in a pro-immune context, finding that both ALRs bind NETs in vitro and in SLE renal tissues. We demonstrate that ALR binding causes NETs to resist degradation by DNase I, suggesting a mechanism whereby extracellular ALR-NET interactions may promote sustained IFN signaling. Our work suggests that extracellular ALRs bind NETs, leading to DNase resistant nucleoprotein fibers that are targeted as autoantigens in SLE.